N.V. OMILAENKO, S.V. VOROBYEV, A.V. SAFRONENKO, S.Ya. SOBOLEVA

Rostov State Medical University, 29 Nakhichevanskiy pereulok, Rostov-on-Don, Russian Federation, 344718

Omilaenko N.V. — postgraduate student of the Department of Endocrinology with a course of Pediatric Endocrinology, tel. +7-926-209-65-57, e-mail: omila13@mail.ru

Vorobyev S.V. — D. Med. Sc., Professor, Head of the Department of Endocrinology with a course of Pediatric Endocrinology, tel. +7-903-463-59-43, e-mail: endocrinrostov@mail.ru

Safronenko A.V. — Cand. Med. Sc., Associate Professor of the Department of Pharmacology with the Basics of Clinical Pharmacology, tel. +7-961-310-00-17, e-mail: andrejsaf@mail.ru

Soboleva S.Ya. — Cand. Med. Sc., therapist of the Therapy Department, tel. +7-906-181-66-97, e-mail: endocrinrostov@mail.ru

The article presents the results of a comparative analysis of the dynamics of liver functional status using minute dozes of antibodies to C-end fragment of beta-subunit of the receptor for insulin and antibodies to endothelial NO-synthase, and the standard therapy for 60 patients with diabetes mellitus type 2 and non-alcoholic fatty liver disease. The effect of the target drug on carbohydrate metabolism compared to standard treatment has not been found. The positive effect is found of supplementation of minute dozes of antibodies to C-end fragment beta-subunit of the receptor for insulin and antibodies to endothelial NO-synthase compared to the standard therapy on the insulin resistance syndrome in peripheral tissues, reducing the level of total cholesterol. Optimization of standard therapy has led to a more pronounced influence on fatty infiltration of the liver: favorable changes in the lung organ were observed, objectively measured by dynamic echogepatodensitometry.

Key words: type 2 diabetes, fatty liver disease, free antibodies to C-end fragment of beta-subunit of the insulin receptor, antibodies to endothelial NO-synthase.

REFERENCES

1. Dedov I.I., Shestakova M.V. Personalizirovannaya terapiya sakharnogo diabeta: put’ ot bolezni k bol’nomu. Terapevticheskiy arkhiv, 2014, no. 10, pp. 4-9 (in Russ.).

2. Dedov I.I., Mel’nichenko G.A., Troshina E.A., Mazurina N.V., Ogneva N.A., Yashkov Yu.I., Il’in A.V. Indicators of carbohydrate metabolism and production of incretins in patients with Morbid obesity nym, including undergoing bypass surgery Biliopancreatic. Ozhirenie i metabolizm, 2014, no. 1, pp. 24-31 (in Russ.).

3. Slyadnev S.A., Koroy P.V. Metabolic syndrome and non-alcoholic fatty liver disease. Meditsinskiy vestnik Severnogo Kavkaza, 2013, no. 4, pp. 86-87 (in Russ.).

4. Gholam P.M., Flanebaum L., Machan J.T. et al. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol, 2007, vol. 102, pp. 399-408.

5. Gaus O.V., Akhmedov V.A. Pathogenic features of organ damage gepatobili-ary system in patients with metabolic syndrome. Kazanskiy meditsinskiy zhurnal, 2014, no. 1, pp. 70-74 (in Russ.).

6. Drapkina O.M., Ivashkin V.T. Epidemiological features of nonalcoholic fatty liver disease in Russia. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2014, no. 4, pp. 32-38 (in Russ.).

7. Kheyfets I.A., Spasov A.A., Voronkova M.P., Dugina Yu.L., Epshteyn O.I. The study hypoglycemic activity Subetto and rosiglitazone on the model of streptozotocin diabetes in rats. Byulleten’ eksperimental’noy biologii i meditsiny, 2012, vol. 153, no.1, pp. 62-64 (in Russ.).

8. Nicoll J., Gorbunov Evgeniy A., Tarasov Sergey A., Epstein Oleg I. Subetta treatment increases adiponectin secretion by mature human adipocytes in vitro. International Journal of Endocrinology, 2013, rr. 1-4. http://dx.doi.org/10.1155/2013/925874

9. Bailbe D., Philippe E., Gorbunov E., Tarasov S., Epstein O., Portha B. The Novel Oral Drug Subetta Exerts an Antidiabetic Effect in the Diabetic Goto-Kakizaki Rat: Comparison with Rosiglitazone. Journal of Diabetes Research, 2013, pp. 1-9. http://dx.doi.org/10.1155/2013/763125

10. Savel’ev V.S., Petukhov V.A., Karalkin A.V., Kuznetsov M.R. et al. Sposob diagnostiki diffuznogo zhirovogo gepatoza. Patent RF 2204327, opubl. 20.03.2000 [A method of diagnosis of diffuse fatty liver. RF 2204327, published patent. 20.03.2000].